

Supplemental data for
Serosurvey of SARS-COV-2 at a large public university

Ching-Wen Hou¹, Stacy Williams¹, Kylee Taylor¹, Veronica Boyle¹, Bradley Bobbett¹, Joseph Kouvetakis¹, Keana Nguyen¹, Aaron McDonald¹, Valerie Harris², Benjamin Nussle¹, Phillip Scharf³, Megan Jehn⁴, Timothy Lant², Mitch Magee¹, Yunro Chung^{1,5}, Joshua Labaer¹, Vel Murugan ^{1*}

¹Virginia G. Piper Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA

²Office of VP Research Development, Arizona State University, Tempe, AZ, USA

³College of Liberal Arts and Sciences, Arizona State University, Tempe, AZ, USA

⁴School of Human Evolution and Social Change, Arizona State University, Tempe, AZ, USA


⁵College of Health Solutions, Arizona State University, Phoenix, AZ, USA

*Corresponding author. Email: vel.murugan@asu.edu


Supplementary Table 1: Manufacturer reported sensitivity and specificity of EUA authorized tests used in this study

Assay	Sensitivity (positive percent agreement at \geq 15 days post symptom onset)	Specificity
Chemiluminescent assay: Beckman (Anti-RBD IgG)	98.9%	100%
Later flow assay: Clarity (Anti-RBD IgG)	96.15%	100%
Later flow assay: Megna (Anti-NC IgG)	95%	99.3%
ELISA: Bio-Rad (Anti-NC IgM/IgG/IgA)	100%	98.86%
Electrochemiluminescence assay: MSD* (Anti-NC IgG)	93.8%	100%
Electrochemiluminescence assay: MSD* (Anti-RBD IgG)	98.3%	98.5%

*MSD is not a EUA authorized test. It is a validated assay meets the clinical laboratory standards institute guidelines.



Supplementary Figure 1: Anti-RBD antibody decay post-vaccination. The antibody level is determined by the Beckman immunoassay. The linear regression of different vaccines to estimate vaccine decay.



Supplementary Figure 2: Anti-Nucleocapsid antibody decay post-infection. The antibody level is determined by the MSD. The linear regression was to estimate antibody decay.